혈액 검사 결과지를 받아 들고 수치가 뭘 의미하는지 막막했던 경험이 있을 것이다. 중성지방, HDL 콜레스테롤, 공복혈당 — 이 세 가지 수치를 하나의 공식으로 합산하면 당뇨, 고혈압, 심장병, 뇌졸중이 동시에 찾아올 위험을 수 년 전에 예측할 수 있다는 연구 결과가 나왔다.
*Journal of Health, Population and Nutrition*에 발표된 이 전향적 코호트 연구는 중국 중·노년층 종단 연구(CHARLS)와 영국 고령화 종단 연구(ELSA) 데이터를 결합해 45세 이상 성인 9,297명을 최대 7년간 추적했다. 두 나라의 데이터를 동시에 분석함으로써 문화적·유전적 배경에 관계없이 결과가 일관되게 나타나는지 검증했다.
TyG-NHHR 지수란 중성지방-공복혈당 지수(TyG)에 비-HDL 콜레스테롤 대 HDL 콜레스테롤 비율(NHHR)을 곱한 값이다. 이 지수는 특수 장비 없이 통상적인 혈액 검사로 산출할 수 있어 의료 자원이 제한된 환경에서도 활용 가능하다는 장점이 있다.
7년 추적 기간 동안 참가자 19.9%(1,851명)가 복합 심혈관대사 질환(CMM)을 새로 진단받았다. TyG-NHHR 지수가 표준편차 1단위 오를 때마다 CMM 위험이 13% 증가했으며(HR 1.13, 95% CI 1.09-1.17), 지수가 가장 높은 사분위 그룹은 가장 낮은 그룹보다 위험이 56% 높았다(HR 1.56, 95% CI 1.33-1.83). 단순한 시점 수치가 아닌 장기 누적 노출과 '지속적으로 높은 궤적'에서 연관성이 더욱 강하게 나타났다.
작용 기전을 분석한 결과, 인슐린 저항성이 이상지질혈증과 CMM 사이를 유의하게 매개하는 것으로 밝혀졌다. 즉, 혈액 내 지질 이상이 인슐린 저항성을 통해 복합 심혈관대사 질환으로 이어지는 경로가 주된 메커니즘이며, 반대 방향의 경로는 제한적이었다.
이 연구의 의의는 복잡한 대사 이상을 하나의 지수로 요약해 조기 위험 식별에 사용할 수 있다는 점이다. 단, 이번 연구는 관찰 연구이므로 인과 관계를 단정할 수는 없으며, TyG-NHHR 지수가 임상적으로 어느 수준에서 개입해야 하는지는 추가 연구가 필요하다.
정기 건강검진에서 중성지방, 공복혈당, HDL 콜레스테롤 수치를 함께 확인하는 습관이 중요하다. 세 수치 중 두 가지 이상이 경계 범위에 해당한다면 주치의와 생활 습관 개선을 상담하는 것이 바람직하다. 운동, 식이 조절, 금연은 인슐린 저항성과 이상지질혈증을 동시에 개선하는 가장 효과적인 비약물적 방법이다.
📖 *Association of a novel triglyceride-glucose and non-HDL-to-HDL cholesterol ratio (TyG-NHHR) index with cardiometabolic multimorbidity: a dual-cohort prospective study in Chinese and European adults (전향적 코호트 연구, 9,297명)* |
논문 원문
※ 이 기사는 의학 논문을 바탕으로 작성되었습니다. 개인 건강 상태에 따라 다를 수 있으니 전문의와 상담하세요.
Every year, millions of people receive routine blood test results they barely understand — a number for triglycerides here, an HDL cholesterol reading there. But what if combining those numbers into a single calculation could predict, years in advance, whether you're heading toward heart disease, stroke, hypertension, or diabetes all at once?
That's the premise behind a large prospective study published in the *Journal of Health, Population and Nutrition*, which followed 9,297 middle-aged and older adults across two continents for up to seven years to evaluate a novel metabolic index called TyG-NHHR.
What Is TyG-NHHR?
The TyG-NHHR index multiplies the triglyceride-glucose (TyG) index — a widely used proxy for insulin resistance — by the ratio of non-HDL to HDL cholesterol (NHHR), a marker of atherogenic dyslipidemia. Both components can be derived from standard fasting blood panels, requiring no special equipment or additional lab costs. This makes the combined index particularly appealing for resource-limited healthcare settings.
Researchers analyzed data from the China Health and Retirement Longitudinal Study (CHARLS, 2011–2018) and the English Longitudinal Study of Ageing (ELSA, 2008–2014), excluding participants who already had cardiometabolic conditions at baseline. The final sample of 9,297 adults (aged 45 and older) was tracked for a median of seven years.
The Numbers Tell a Stark Story
During the follow-up period, 19.9% of participants — nearly one in five — developed cardiometabolic multimorbidity (CMM), defined as the new onset of at least two conditions among heart disease, stroke, hypertension, and diabetes.
The association between TyG-NHHR and CMM was consistent and dose-dependent. For every standard deviation increase in baseline TyG-NHHR, the risk of developing CMM rose by 13% (hazard ratio 1.13, 95% CI 1.09–1.17). Participants in the highest quartile of the index faced a 56% greater risk than those in the lowest quartile (HR 1.56, 95% CI 1.33–1.83).
Importantly, the relationship wasn't limited to a single time point. Cumulative exposure — calculated by averaging TyG-NHHR across multiple measurements — and persistently elevated trajectories showed even stronger associations with CMM. This suggests that sustained metabolic dysregulation, rather than a brief spike, is the more meaningful risk signal.
A restricted cubic spline analysis confirmed a linear dose-response relationship: there was no apparent "safe" threshold below which higher TyG-NHHR posed no additional risk.
Why Insulin Resistance Is the Central Culprit
To understand the mechanism, researchers conducted mediation analysis. They found that insulin resistance accounted for a significant share of the pathway connecting atherogenic dyslipidemia to CMM development. In plainer terms: abnormal blood lipids appear to promote insulin resistance, which then drives the development of multiple cardiometabolic conditions simultaneously. The reverse pathway — from CMM back to dyslipidemia — was comparatively weak.
This finding aligns with established biology. Chronic insulin resistance impairs glucose uptake in tissues, promotes hepatic lipid production, and contributes to endothelial dysfunction — all of which accelerate the progression of cardiovascular and metabolic disease in tandem.
Global Consistency, Important Caveats
The study's strength lies in its cross-population validation. Results were consistent across Chinese and European cohorts, different age groups, sexes, and medication statuses — suggesting TyG-NHHR captures a universal metabolic risk pathway rather than a population-specific quirk.
That said, because this is an observational study, causality cannot be firmly established. The optimal clinical threshold for TyG-NHHR — the point at which intervention is warranted — has not been defined and requires further prospective validation.
What This Means for Your Health
When you receive your next blood panel, pay attention to all three components: fasting blood glucose, triglycerides, and HDL cholesterol. If two or more fall in borderline ranges, talk to your doctor about combined metabolic risk even if no single value is alarming on its own.
Lifestyle interventions that simultaneously target insulin resistance and dyslipidemia — regular aerobic exercise, a diet low in refined carbohydrates and saturated fat, smoking cessation, and adequate sleep — remain the most effective non-pharmacological strategies for reducing composite cardiometabolic risk.
📖 *Association of a novel triglyceride-glucose and non-HDL-to-HDL cholesterol ratio (TyG-NHHR) index with cardiometabolic multimorbidity: a dual-cohort prospective study in Chinese and European adults (Prospective cohort study, n=9,297)* |
Source
※ This article is based on a published medical study. Individual health circumstances vary — consult your physician before making any changes to your care.
